This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can UUUU's Rare Earths Revolutionize EV Magnet Supply Chains?
by Madhurima Das
Energy Fuels hits a milestone as its NdPr oxide is turned into EV-grade rare earth magnets by POSCO, advancing a U.S.-based supply chain.
Can UUUU and Vulcan Elements Strengthen U.S. Rare Earth Magnet Supply?
by Madhurima Das
Energy Fuels partners with Vulcan to build a China-free rare earth magnet supply chain, as it advances high-purity NdPr and Dy oxide production.
Chemours Enters Strategic Agreement With SRF to Boost Supply
by Zacks Equity Research
CC partners with SRF to expand global supply chain, boost operational flexibility and strengthen its high-value product mix.
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
by Zacks Equity Research
CC posts Q2 earnings and sales beat driven by volume and pricing gains, but issues softer sequential guidance.
Chemours (CC) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of +26.09% and +2.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Huntsman (HUN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Huntsman (HUN) delivered earnings and revenue surprises of -33.33% and -1.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CC Sees Gains From Opteon Growth in Q2, Navigates Disruptions in TT
by Zacks Equity Research
Chemours' second-quarter sales are expected to be at the high end of its guidance as TT disruptions get offset by Opteon demand boosts.
Chemours (CC) Down 7.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICL Group's Earnings Surpass Estimates, Revenues Lag in Q1
by Zacks Equity Research
ICL sees higher sales across its Industrial Products, Phosphate Solutions and Growing Solutions units in Q1.
Chemours Joins DataVolt to Advance Liquid Cooling for AI Data Centers
by Zacks Equity Research
The deal will enable CC to focus on improving data center efficiency by using two-phase direct-to-chip, two-phase immersion cooling and other new methods.
Flexible Solutions Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
FSI sees lower sales in the first quarter as reduced customer orders led to declines across its segments.
Koppers Earnings Beat, Revenues Fall Short of Estimates in Q1
by Zacks Equity Research
KOP gains on higher prices and reduced costs in the Railroad and Utility Products and Services segment in the first quarter.
Chemours & Navin Fluorine Partner to Produce Liquid Cooling Product
by Zacks Equity Research
CC partners with Navin Fluorine to facilitate the adoption of two-phase liquid cooling.
Innospec's Earnings Surpass Estimates in Q1, Revenues Miss
by Zacks Equity Research
IOSP sees strong results in the Fuel Specialties unit in Q1 with higher margins driving a double-digit year-over-year increase in operating income.
Chemours' Q1 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
CC's first-quarter earnings miss estimates, but revenues beat the same on increased sales from Titanium Technologies and Thermal & Specialized Solutions.
Zacks Market Edge Highlights: WHR, PFE, CVX, CC and DOW
by Zacks Equity Research
WHR, PFE, CVX, CC and DOW have been highlighted in this Market Edge article.
Are Your Mega-High Stock Dividends Safe?
by Tracey Ryniec
Tracey Ryniec, Zacks Senior Stock Strategist, and Bryan Hayes, editor of Zacks Income Investor newsletter, discuss 5 popular stocks with high dividend yields. Can the dividend be trusted?
Chemours (CC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q1 Earnings Miss Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -31.58% and 0.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Innospec (IOSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Innospec (IOSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albemarle (ALB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Albemarle (ALB) delivered earnings and revenue surprises of 70.97% and 8.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AkzoNobel (AKZOY) Moves 8.0% Higher: Will This Strength Last?
by Zacks Equity Research
AkzoNobel (AKZOY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Chemours (CC) Down 14% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.